Core Viewpoint - Aimee Vaccine has achieved a significant breakthrough in the pneumonia vaccine sector with the approval of its 20-valent pneumonia conjugate vaccine for clinical trials, enhancing its competitive position in the domestic high-end market [1][3][6]. Group 1: Product Development and Market Position - The newly approved 20-valent pneumonia conjugate vaccine builds on the existing 13-valent vaccine, adding 7 new serotypes to cover a total of 20 serotypes of pneumococcus, targeting individuals aged 2 months and older [3][7]. - The pneumonia conjugate vaccine is considered a "crown" product in the vaccine industry, with Pfizer's Prevnar series projected to generate global sales of $6.411 billion in 2024, highlighting the high commercial value of this market [4][5]. - Currently, Pfizer is the only company with a 20-valent pneumonia conjugate vaccine available internationally, leaving a gap in the domestic market that Aimee Vaccine aims to fill [6]. Group 2: Market Demand and Growth Potential - The market demand for pneumonia vaccines is underscored by the significant penetration rate gap; for instance, the penetration rate of the 13-valent vaccine in China is approximately 25%, compared to over 80% in the U.S., indicating substantial growth potential in the Chinese market [8]. - Aimee Vaccine has established a product matrix in the pneumonia sector, including the 13-valent and 24-valent vaccines, which positions the company to benefit from a clear growth model supported by market space, technological iterations, and opportunities for international expansion [7][8]. Group 3: Financial Outlook and Innovation - The company is at a critical turning point, with a clear path to profitability as multiple core products enter late-stage clinical trials or production phases, following significant R&D investments [10][11]. - Aimee Vaccine's R&D expenses are expected to decrease by 39% by 2025, coinciding with the completion of major clinical trials, and the company is projected to achieve profitability by 2026 [10]. - The recent approval of the 20-valent pneumonia conjugate vaccine reflects the company's ongoing innovation capabilities, with several innovative vaccines nearing market launch, providing solid performance support and cash flow [10][11].

Core Viewpoint - The announcement highlights the successful completion of Phase III clinical trials for the company's high-titer human diploid rabies vaccine, marking a significant step towards commercialization and establishing a solid foundation for future market entry [1][2]. Group 1: Product Development and Innovation - The new high-titer human diploid rabies vaccine represents a major technological upgrade in the rabies vaccine field, demonstrating significantly higher efficacy compared to existing human diploid vaccines under the same dosage conditions [1][2]. - The company has overcome traditional production challenges related to low virus titer and yield through optimized purification processes, enhancing product quality and safety [2]. - The vaccine utilizes human diploid cells instead of Vero cells, providing a natural safety advantage and aligning with WHO recommendations as the gold standard for rabies vaccines [3]. Group 2: Market Potential and Competitive Advantage - China is projected to become the largest rabies vaccine market globally, with an estimated market value of 14.8 billion yuan by 2030, driven by product updates and increased vaccination rates [2]. - The new vaccine offers flexible administration methods, including the "five-dose method," "simple four-dose method," and "2-1-1 four-dose method," making it more convenient for healthcare providers [2]. - The company aims to solidify its position as the second-largest supplier of rabies vaccines globally, enhancing its competitive edge and contributing to sustainable growth through a diversified product portfolio [3].

Core Viewpoint - The announcement by the company regarding the completion of Phase III clinical trials for its high-titer human diploid rabies vaccine marks a significant advancement towards commercialization, establishing a solid foundation for future market entry [1] Group 1: Product Development and Innovation - The newly developed high-titer human diploid rabies vaccine represents a major technological upgrade in the rabies vaccine field, demonstrating significantly higher efficacy compared to existing human diploid vaccines [1][2] - The vaccine utilizes human diploid cells instead of Vero cells, providing a natural safety advantage and resulting in a product that is 3 to 5 times more expensive than traditional Vero cell vaccines, thus offering higher added value [1][2] Group 2: Market Potential and Demand - China is projected to become the largest rabies vaccine market globally, with an estimated market value of 14.8 billion yuan by 2030, driven by product updates and increased vaccination rates [2] - The new vaccine offers flexible administration methods, including the "five-dose method," "simple four-dose method," and "2-1-1 four-dose method," making it more convenient for healthcare providers [2] Group 3: Competitive Position and Future Outlook - The company is the second-largest supplier of rabies vaccines globally and aims to lead in technological upgrades within the rabies vaccine sector, enhancing product quality and safety [3] - The approval of this new product is expected to enrich the company's product portfolio, strengthen its core competitiveness, and contribute additional revenue, thereby supporting sustainable growth [3]

Core Viewpoint - The announcement by Ai Mei Vaccine (06660.HK) indicates the successful completion of Phase III clinical trials for its high-efficacy human diploid rabies vaccine, marking a significant step towards commercialization [1] Group 1: Product Development - The new human diploid rabies vaccine features a significantly higher efficacy compared to existing products on the market, representing a major technological upgrade in the rabies vaccine field [1] - Animal trials have shown that the vaccine generates a high level of protective antibodies, outperforming currently available human diploid rabies vaccines under the same dosage conditions [1] Group 2: Market Position and Strategy - The World Health Organization (WHO) recommends human diploid rabies vaccines as the gold standard, and the company is positioned as the second-largest supplier of rabies vaccines globally [1] - The company aims to lead the technological upgrade in the rabies vaccine market, providing higher quality and safer vaccine products, thereby reinforcing its leading position and promoting sustainable development [1] Group 3: Future Prospects - The approval of this new product is expected to enhance the company's product portfolio, creating synergies with existing rabies vaccine series and strengthening its core competitiveness [1] - As part of its global strategy, the new vaccine is anticipated to contribute additional revenue and solidify the company's market position, providing new momentum for sustained and stable growth [1]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內 容 概 不 負 責，對 其 準 確 性 或 完 整 性 亦 不 發 表 任 何 聲 明，並 明 確 表 示，概 不對因本公告全部或任何部份內容而產生或因倚賴該等內容而引致的 任 何 損 失 承 擔 任 何 責 任。 AIM Vaccine Co., Ltd. 艾美疫苗股份有限公司 本 公 告 由 艾 美 疫 苗 股 份 有 限 公 司（「本公司」，連 同 其 附 屬 公 司 統 稱「本 集 團」）自 願 作 出，以 告 知 本 公 司 股 東 及 潛 在 投 資 者 本 集 團 的 最 新 業 務 發 展。 （於 中 華 人 民 共 和 國 註 冊 成 立 的 股 份 有 限 公 司） （股 份 代 號：06660） 自願性公告 本 集 團 研 發 的 迭 代 工 藝 高 效 價 人 二 倍 體 狂 犬 疫 苗，目 前III期臨床現場工 作 已 順 利 完 成。這 標 誌 著 該 疫 苗 正 式 進 入 新 的 階 段，為 未 來 商 業 化 上 市 奠 定 堅 實 的 基 礎。 該 產 品 是 一 款 迭 代 升 級 的 人 二 倍 體 狂 犬 ...

Core Viewpoint - The biotechnology sector in Hong Kong is experiencing a surge, with companies like Ai Mei Vaccine gaining significant attention due to their stable performance and innovative technologies [1] Group 1: Company Performance - Ai Mei Vaccine reported steady revenue growth for the first half of 2025, with key innovative products nearing market launch, leading to expectations of improved performance and valuation [1][2] - The company has four major innovative products entering the market, including the 13-valent pneumococcal conjugate vaccine, which has a significant market potential in China, projected to exceed RMB 20 billion by 2030 [2][3] Group 2: Product Development - Ai Mei Vaccine is advancing in the rabies vaccine sector with multiple products, including a serum-free rabies vaccine and an mRNA rabies vaccine, positioning itself as a leader in a market expected to reach RMB 20 billion by 2030 [3] - The company holds 20 vaccine candidates in development across 12 disease areas, with 23 clinical approvals and 24 clinical trials ongoing, including seven innovative vaccines [3] Group 3: Market Potential and Valuation - The 13-valent pneumococcal conjugate vaccine is anticipated to capture a significant market share, with a penetration rate in China estimated at 25.9%, compared to over 80% in the U.S., indicating substantial growth opportunities [2] - DBS Bank's report suggests that Ai Mei Vaccine's current stock price is at the lower end of its peers' valuation range, with a projected fair target price of HKD 8.3 per share by 2026, indicating a potential upside of nearly 600% [4]

Group 1 - The Hong Kong innovative drug sector has significantly outperformed the market since 2025, with 49 pharmaceutical companies seeing stock price increases exceeding 100% [1] - The recent listing of Zhonghui Biotech has catalyzed a bullish trend in multiple biopharmaceutical stocks, including vaccine companies [1] - Chinese innovative drug companies are actively developing original innovative drugs, which are expected to create sustainable overseas opportunities [1] Group 2 - Aimee Vaccine (06660) reported stable revenue in its semi-annual report for the first half of 2025, with reduced R&D expenses and optimized operating costs [1] - The company has 20 vaccine products in development across 12 disease areas, with a pipeline covering the top ten global vaccine products [1] - Aimee has received clinical approval for two mRNA vaccines in both China and the U.S., validating its innovative capabilities and global market strategy [2] Group 3 - Aimee Vaccine is leading in the mRNA technology field, with its platform validated through extensive clinical trials, ensuring safety and efficacy [2] - The company has several key vaccine products nearing market launch, indicating an upcoming performance improvement [2] - The 13-valent pneumococcal conjugate vaccine is one of the broadest vaccines available, with a significant global market gap of 180 million doses [3] Group 4 - The innovative drug sector in Hong Kong is experiencing a new wave of development opportunities, with Aimee Vaccine positioned for rapid performance improvement due to its innovative vaccine R&D capabilities [4] - The company's stock price has strong upward momentum driven by industry growth and its improving fundamentals [4]

Core Viewpoint - The company, Ai Mei Vaccine, is poised for significant growth with the upcoming commercialization of key vaccine products and a reduction in R&D expenses, leading to a strong financial outlook for 2025 and beyond [1][2] Group 1: Financial Performance - Ai Mei Vaccine reported stable revenue for the first half of 2025, supported by the impending launch of four major vaccine products [1] - The company is expected to achieve profitability by 2026, with sales projected to grow at a compound annual growth rate (CAGR) of 45% from 2025 to 2027 [2] Group 2: Product Development - Four major vaccine products are nearing commercialization: - The registration application for the updated rabies vaccine has been accepted - The 13-valent pneumonia conjugate vaccine has applied for registration and completed on-site verification - The 23-valent pneumonia polysaccharide vaccine has completed Phase III clinical serum testing and is entering the statistical unblinding phase - The updated high-efficiency diploid rabies vaccine is in Phase III clinical trials, with a registration application expected in 2026 [1] - The company has 20 vaccine products in development across 12 disease areas, with 23 clinical approvals and 24 ongoing clinical trials, including 7 innovative Class 1 vaccines [1] Group 3: Market Expansion - Ai Mei Vaccine has successfully entered the African market with its quadrivalent meningococcal polysaccharide vaccine and is registering in Central Asia - The rabies vaccine has made its debut in the Central American market - The hepatitis B vaccine is actively undergoing registration processes in Southeast Asia, while the hepatitis A vaccine is progressing in South Asia [1]